228 related articles for article (PubMed ID: 10459803)
1. Pneumococcal macrolide resistance--myth or reality?
Amsden GW
J Antimicrob Chemother; 1999 Jul; 44(1):1-6. PubMed ID: 10459803
[TBL] [Abstract][Full Text] [Related]
2. Antimicrobial susceptibility of Streptococcus pneumoniae isolates from vaccinated and non-vaccinated patients with a clinically confirmed diagnosis of community-acquired pneumonia in Belgium.
Lismond A; Carbonnelle S; Verhaegen J; Schatt P; De Bel A; Jordens P; Jacobs F; Dediste A; Verschuren F; Huang TD; Tulkens PM; Glupczynski Y; Van Bambeke F
Int J Antimicrob Agents; 2012 Mar; 39(3):208-16. PubMed ID: 22245497
[TBL] [Abstract][Full Text] [Related]
3. Activities of 16-membered ring macrolides and telithromycin against different genotypes of erythromycin-susceptible and erythromycin-resistant Streptococcus pyogenes and Streptococcus pneumoniae.
Mazzariol A; Koncan R; Vitali LA; Cornaglia G
J Antimicrob Chemother; 2007 Jun; 59(6):1171-6. PubMed ID: 17405779
[TBL] [Abstract][Full Text] [Related]
4. Macrolide resistance among invasive Streptococcus pneumoniae isolates.
Hyde TB; Gay K; Stephens DS; Vugia DJ; Pass M; Johnson S; Barrett NL; Schaffner W; Cieslak PR; Maupin PS; Zell ER; Jorgensen JH; Facklam RR; Whitney CG;
JAMA; 2001 Oct; 286(15):1857-62. PubMed ID: 11597287
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of azithromycin in the treatment of community-acquired pneumonia, including patients with macrolide-resistant Streptococcus pneumoniae infection.
Yanagihara K; Izumikawa K; Higa F; Tateyama M; Tokimatsu I; Hiramatsu K; Fujita J; Kadota J; Kohno S
Intern Med; 2009; 48(7):527-35. PubMed ID: 19336954
[TBL] [Abstract][Full Text] [Related]
6. In vitro activity and pharmacodynamics of azithromycin and clarithromycin against Streptococcus pneumoniae based on serum and intrapulmonary pharmacokinetics.
Kays MB; Denys GA
Clin Ther; 2001 Mar; 23(3):413-24. PubMed ID: 11318076
[TBL] [Abstract][Full Text] [Related]
7. Mechanism of Macrolide-Induced Inhibition of Pneumolysin Release Involves Impairment of Autolysin Release in Macrolide-Resistant Streptococcus pneumoniae.
Domon H; Maekawa T; Yonezawa D; Nagai K; Oda M; Yanagihara K; Terao Y
Antimicrob Agents Chemother; 2018 Nov; 62(11):. PubMed ID: 30181369
[No Abstract] [Full Text] [Related]
8. Therapeutic options for pneumococcal pneumonia in Turkey.
Oncu S; Erdem H; Pahsa A
Clin Ther; 2005 Jun; 27(6):674-83. PubMed ID: 16117975
[TBL] [Abstract][Full Text] [Related]
9. Clinical relevance of antimicrobial resistance in the management of pneumococcal community-acquired pneumonia.
Feldman C
J Lab Clin Med; 2004 May; 143(5):269-83. PubMed ID: 15122171
[TBL] [Abstract][Full Text] [Related]
10. Contradiction between in vitro and clinical outcome: intravenous followed by oral azithromycin therapy demonstrated clinical efficacy in macrolide-resistant pneumococcal pneumonia.
Kohno S; Tateda K; Kadota J; Fujita J; Niki Y; Watanabe A; Nagashima M
J Infect Chemother; 2014 Mar; 20(3):199-207. PubMed ID: 24477328
[TBL] [Abstract][Full Text] [Related]
11. Clinical implications of macrolide resistance in community-acquired respiratory tract infections.
Hoban DJ; Zhanel GG
Expert Rev Anti Infect Ther; 2006 Dec; 4(6):973-80. PubMed ID: 17181414
[TBL] [Abstract][Full Text] [Related]
12. Macrolide resistance among middle ear isolates of Streptococcus pneumoniae observed at eight United States pediatric centers: prevalence of M and MLSB phenotypes.
Mason EO; Wald ER; Bradley JS; Barson WJ; Kaplan SL;
Pediatr Infect Dis J; 2003 Jul; 22(7):623-7. PubMed ID: 12867838
[TBL] [Abstract][Full Text] [Related]
13. Streptococcus pneumoniae bacteraemia: pharmacodynamic correlations with outcome and macrolide resistance--a controlled study.
Schentag JJ; Klugman KP; Yu VL; Adelman MH; Wilton GJ; Chiou CC; Patel M; Lavin B; Paladino JA
Int J Antimicrob Agents; 2007 Sep; 30(3):264-9. PubMed ID: 17587549
[TBL] [Abstract][Full Text] [Related]
14. [Streptococcus pneumoniae strains resistance to macrolide, lincosamide, streptogramin, oxazolidinone and ketolide].
Sener B; Köseoğlu O; Fişenk I; Hasçelik G; Günalp A
Mikrobiyol Bul; 2002 Apr; 36(2):125-31. PubMed ID: 12652863
[TBL] [Abstract][Full Text] [Related]
15. In vitro activity of six macrolides, clindamycin and tetracycline on Streptococcus pneumoniae with different penicillin susceptibilities.
Poulsen RL; Knudsen JD; Petersen MB; Fuursted K; Espersen F; Frimodt-Møller N
APMIS; 1996 Mar; 104(3):227-33. PubMed ID: 8611198
[TBL] [Abstract][Full Text] [Related]
16. Antimicrobial susceptibility of community-acquired respiratory tract pathogens in the UK during 2002/3 determined locally and centrally by BSAC methods.
Morrissey I; Robbins M; Viljoen L; Brown DF
J Antimicrob Chemother; 2005 Feb; 55(2):200-8. PubMed ID: 15649996
[TBL] [Abstract][Full Text] [Related]
17. Beta-lactam and macrolide resistance and serotype distribution among Streptococcus pneumoniae isolates from Saudi Arabia.
Fouda SI; Kadry AA; Shibl AM
J Chemother; 2004 Dec; 16(6):517-23. PubMed ID: 15700841
[TBL] [Abstract][Full Text] [Related]
18. Macrolide resistance in Streptococcus pneumoniae isolated from patients with community-acquired lower respiratory tract infections in Portugal: results of a 3-year (1999-2001) multicenter surveillance study.
Melo-Cristino J; Ramirez M; Serrano N; Hänscheid T;
Microb Drug Resist; 2003; 9(1):73-80. PubMed ID: 12705685
[TBL] [Abstract][Full Text] [Related]
19. Antipneumococcal activities of two novel macrolides, GW 773546 and GW 708408, compared with those of erythromycin, azithromycin, clarithromycin, clindamycin, and telithromycin.
Matic V; Kosowska K; Bozdogan B; Kelly LM; Smith K; Ednie LM; Lin G; Credito KL; Clark CL; McGhee P; Pankuch GA; Jacobs MR; Appelbaum PC
Antimicrob Agents Chemother; 2004 Nov; 48(11):4103-12. PubMed ID: 15504828
[TBL] [Abstract][Full Text] [Related]
20. The comparative development of elevated resistance to macrolides in community-acquired pneumonia caused by Streptococcus pneumoniae.
Yayan J
Drug Des Devel Ther; 2014; 8():1733-43. PubMed ID: 25336917
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
